Lenvatinib Plus Pembrolizumab Improves Outcomes in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma | Zendy

AI Assistant Blog Pricing

Open Access

Lenvatinib Plus Pembrolizumab Improves Outcomes in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma

Author(s) -

Motzer

Publication year - 2021

Publication title -

journal of clinical outcomes management

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 0.126

H-Index - 19

eISSN - 1938-1336

pISSN - 1079-6533

DOI - 10.12788/jcom.0044

Subject(s) - lenvatinib , medicine , pembrolizumab , renal cell carcinoma , oncology , urology , immunotherapy , cancer , sorafenib , hepatocellular carcinoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.